Search results
Results from the WOW.Com Content Network
Lipid-lowering agents, also sometimes referred to as hypolipidemic agents, cholesterol-lowering drugs, or antihyperlipidemic agents are a diverse group of pharmaceuticals that are used to lower the level of lipids and lipoproteins, such as cholesterol, in the blood (hyperlipidemia). The American Heart Association recommends the descriptor ...
ATC code C10 Lipid modifying agents is a therapeutic subgroup of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the World Health Organization (WHO) for the classification of drugs and other medical products. [1] [2] [3] Subgroup C10 is part of the anatomical group C Cardiovascular system. [4]
Drug interactions are possible, but studies have not shown that these statins increase exposure to ciclosporin. [60] HIV-positive people taking protease inhibitors: Atorvastatin, pravastatin or fluvastatin: Negative interactions are more likely with other choices. [61] Persons taking gemfibrozil, a non-statin lipid-lowering drug Atorvastatin
This page was last edited on 12 February 2016, at 04:17 (UTC).; Text is available under the Creative Commons Attribution-ShareAlike 4.0 License; additional terms may apply.
Phytosterols are widely recognized as having a proven LDL cholesterol lowering efficacy' [61] A 2018 review found a dose-response relationship for phytosterols, with intakes of 1.5 to 3 g/day lowering LDL-C by 7.5% to 12%, [62] but reviews as of 2017 had found no data indicating that the consumption of phytosterols may reduce the risk of CVD. [63]
Dyslipidemia is a risk factor for the development of atherosclerotic cardiovascular diseases, [1] which include coronary artery disease, cerebrovascular disease, and peripheral artery disease. [1] Although dyslipidemia is a risk factor for cardiovascular disease, abnormal levels do not mean that lipid lowering agents need to be started. [2]
The lipid hypothesis (also known as the cholesterol hypothesis) is a medical theory postulating a link between blood cholesterol levels and the occurrence of cardiovascular disease. A summary from 1976 described it as: "measures used to lower the plasma lipids in patients with hyperlipidemia will lead to reductions in new events of coronary ...
This enzyme is the target of the widely available cholesterol-lowering drugs known collectively as the statins, which help treat dyslipidemia. HMG-CoA reductase is anchored in the membrane of the endoplasmic reticulum , and was long regarded as having seven transmembrane domains, with the active site located in a long carboxyl terminal domain ...